Clinical Trial Update: A Pharmacokinetic Study of VCT220 With Moderate Renal Impairment Patients [Phase 1]

View source ↗

Summary

This is a Phase 1 pharmacokinetic study of VCT220 in adults with obesity/overweight and moderate renal impairment; the trial has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Obesity

Drugs mentioned

• VCT220

Snippet

Sponsor: Vincentage Pharma Co., Ltd | Conditions: Obesity & Overweight | Phase 1 | Status: COMPLETED